

IN THE CLAIMS

1-91 (Canceled)

92. (Currently Amended) A method of treating ~~a blood disease or disorder~~ hemophilia B in a mammal, comprising:

administering a therapeutically effective dose of Factor IX-expressing recombinant adeno-associated virus (rAAV) particles to a mammalian liver cell, wherein said rAAV particles ~~comprise~~ consist essentially of AAV terminal repeats flanking a constitutive viral promoter, a polynucleotide sequence encoding Factor IX operably linked to ~~a promoter, enhancer, or promoter and enhancer~~ said constitutive promoter, and a bovine growth hormone polyA sequence, wherein following infection of said mammalian cell, Factor IX protein is expressed in the liver cell.

93. (Canceled)

94. (Previously Presented) The method of Claim 92, wherein said Factor IX protein is diffusible and is delivered to the circulating blood.

95. (Canceled)

96. (Currently Amended) The method of Claim ~~[[95]]~~ 92, wherein said constitutive viral promoter is ~~[[the]]~~ one of an MFG promoter, a SV40 promoter, a CMV promoter, and a RSV promoter.

97. (Canceled)

98. (Previously Presented) The method of Claim 92, wherein said administering comprises injecting said rAAV into the portal vasculature of said mammal.

99. (Previously Presented) The method of Claim 92, wherein said administering comprises injecting said rAAV intravenously into said mammal.

100. (Currently Amended) A method ~~of expressing a Factor IX protein for treating~~ hemophilia B in a mammal, comprising:

administering recombinant adeno-associated virus (rAAV) particles to a mammalian liver cell, wherein said rAAV particles ~~comprise~~ consist essentially of AAV terminal repeats flanking a MFG promoter, a polynucleotide encoding Factor IX operably linked to a promoter, enhancer, or promoter and enhancer said- MFG promoter, and a bovine growth hormone polyA sequence, wherein following infection of said mammalian cells, Factor IX protein is expressed in the liver.

101. (Previously Presented) The method of Claim 100, wherein said Factor IX protein is diffusible and is delivered to the circulating blood.

102 - 104 (Canceled)

105. (Previously Presented) The method of Claim 100, wherein said administering comprises injecting said rAAV into the portal vasculature of said mammal.

106. (Previously Presented) The method of Claim 100, wherein said administering comprises injecting said rAAV intravenously into said mammal.

107 - 108 (Canceled)

109. (Currently Amended) A pharmaceutical composition for treating a ~~blood disorder~~ hemophilia B comprising, (a) recombinant adeno-associated virus (rAAV) particles comprising a structural gene encoding human Factor IX, an enhancer, promoter or both an enhancer and a promoter, a splice donor acceptor site or intervening sequence (IVS), and inverted terminal repeats flanking said Factor IX structural gene, said enhancer and/or promoter and said splice donor acceptor site or IVS consisting essentially of AAV terminal repeats flanking a MFG promoter, a polynucleotide encoding Factor IX operably linked to the MFG promoter, a bovine growth hormone polyA sequence, and (b) together with a pharmaceutically acceptable carrier.

110 - 114 (Canceled)

115. (New) A method of expressing Factor IX protein for treating hemophilia B in a mammal, comprising:

administering recombinant adeno-associated virus (rAAV) particles to a mammalian liver cell, wherein said rAAV particles consist essentially of AAV terminal repeats flanking an LSP promoter consisting of the thyroid hormone-binding globulin promoter and two copies of the $\alpha 1$ -microglobulin/bikunin enhancer and a polynucleotide encoding Factor IX operably lined to said LSP promoter, wherein following infection of said mammalian cells, Factor IX protein is expressed in the liver cell.

116. (New) The method of Claim 115, wherein said Factor IX protein is diffusible and is delivered to the circulating blood.

117. (New) The method of Claim 115, wherein said administering comprises injecting said rAAV into the portal vasculature of said mammal.

118. (New) The method of Claim 115, wherein said administering comprises injecting said rAAV intravenously into said mammal.

119. (New) A pharmaceutical composition for treating hemophilia B comprising, rAAV particles consisting essentially of AAV terminal repeats flanking an LSP promoter, said LSP promoter consisting of the thyroid hormone-binding globulin promoter and two copies of the $\alpha 1$ -microglobulin/bikunin enhancer and a polynucleotide encoding Factor IX operably linked to said LSP promoter and a pharmaceutically acceptable carrier.